Adlai Nortye
Trending Articles
Related Content
Regulatory
Eisai enters into agreement with Adlai Nortye for potential anticancer agent
Eisai has entered a licensing agreement granting exclusive rights concerning the research, development, manufacture and marketing of Eisai's in-house discovered potential anticancer agent E7046, to Adlai Nortye Biopharma in all regions outside of Japan (excluding China)